Art

J-GLOBAL ID：201002264471006998   Reference number：10A1024398

A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis

非代償性肝硬変患者におけるトルバプタンの有効性,安全性,及び用量反応を探索的に評価するための多施設,非盲検の投与量決定試験

Author (10)： OKITA Kiwamu (Social Insurance Alliance Shimonoseki Kohsei Hospital, Yamaguchi, JPN) ,  SAKAIDA Isao (Yamaguchi Univ. Graduate School of Medicine, Yamaguchi, JPN) ,  OKADA Mitsuru (Otsuka Pharmaceutical Co., Ltd., Osaka, JPN) ,  KANEKO Akira (NTT West Osaka Hospital, Osaka, JPN) ,  CHAYAMA Kazuaki (Hiroshima Univ., Hiroshima, JPN) ,  KATO Michio (Minami Wakayama Medical Center, Wakayama, JPN) ,  SATA Michio (Kurume Univ. School of Medicine, Kurume, JPN) ,  YOSHIHARA Naomasa (Osaka Rosai Hospital, Osaka, JPN) ,  ONO Noriyuki (Chikugo City Hospital, Chikugo, JPN) ,  MURAWAKI Yoshikazu (Tottori Univ. Medical School Hospital, Tottori, JPN)
Material： Journal of Gastroenterology  (J Gastroenterol)
Volume： 45  Issue： 9  Page： 979-987  Publication year： 2010 
JST Material Number： Z0748A  ISSN： 0944-1174  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *liver cirrhosis ,...
Semi thesaurus term： V2 receptor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A1024398&from=J-GLOBAL&jstjournalNo=Z0748A") }}

JST classification (3)： Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G) ,  Clinical application of drugs acting on urinary system  (GW11020C) ,  Clinical application of drugs acting on digestive system  (GW09020B)

Substance index (2)： OPC-41061 ,  Furosemide

Reference (16)：

• GUYTON, AC. Textbook of medical physiology. 2000, 855-856
• YAMAMURA, Y. OPC-41061, a highly potent human vasopressin V2-receptor antagonist : pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998, 287, 3, 860-867
• DOGGRELL, SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004, 5, 977-983
• COSTELLO-BOERRIGTER, LC. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006, 290, 273-278
• LIEBERMAN, FL. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), a fall in GFR during drug-induced diuresis. J Clin Invest. 1969, 48, 6, 975-981

Terms in the title (12)： 非代償性肝硬変 ,  患者 ,  トルバプタン ,  有効性 ,  安全性 ,  用量 ,  探索 ,  評価 ,  施設 ,  盲 ,  投与量 ,  試験